Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients

Conclusions In our cohort, combined neoadjuvant chemotherapy and radiation therapy was associated with improved pathologic downstaging but showed increased perioperative mortality with no improvement in long-term overall survival. For stage IIIA patients with smaller tumors without local invasion, chemotherapy alone may be the preferred neoadjuvant treatment. Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

In this study, the expression of PRKCZ-AS1 in LUAD tissues and cell lines was notably upregulated. Moreover, knockdown of PRKCZ-AS1 inhibited the proliferation and migration, but promoted apoptosis in LUAD cells. Furthermore, miR-766-5p could bind with PRKCZ-AS1. Besides, the expression miR-766-5p was negatively regulated by PRKCZ-AS1 expression in LUAD cells. Furtherly, PRKCZ-AS1 expression positively regulated the expression of MAPK1. Similarly, the expression of MAPK1 was negatively regulated by miR-766-5p expression. Moreover, the binding ability between miR-766-5p and MAPK1 was confirmed. Furthermore, knockdown of MAP...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide [1]. A significant proportion of patients with non-small cell lung cancer (NSCLC), particularly those with adenocarcinoma histology, carry EGFR mutations, with about 15% in Caucasian adenocarcinoma and 50% in Asian adenocarcinoma are EGFR mutants [1 –3]. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been established as the standard therapy in the first-line treatment of advanced NSCLC with EGFR mutations.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: We newly identified two NSCLC related variants on chromosome 5p15.33. Both TERT-rs33963617 and CLPTM1L-rs77518573 conferred reduced risk for NSCLC in Chinese Han population. PMID: 31935503 [PubMed - as supplied by publisher]
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Publication date: December 2019Source: Chinese Medical Sciences Journal, Volume 34, Issue 4Author(s): Ling Zhang, Lei Sun, Xiaoyan Mu, Youxin JiAbstractA 61-year-old Chinese woman was diagnosed as primary pulmonary adenocarcinoma of left superior lobe with epidermal growth factor receptor (EGFR) 19 del mutation positive. Treatment with icotinib was given, but her disease progressed after 6 months remission. CT-guide needle biopsy for the new lesion in inferior lobe of left lung demonstrated intrapulmonary metastasis, and EGFR gene panel by Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) confir...
Source: Chinese Medical Sciences Journal - Category: General Medicine Source Type: research
Publication date: December 2019Source: Chinese Medical Sciences Journal, Volume 34, Issue 4Author(s): Yi Bao, Juanfen Mo, Jiayuan Wu, Chenxi CaoObjectiveTo investigate the expression and regulation of programmed cell death protein 1 (PD1), B lymphocyte and T lymphocyte attenuator (BTLA) in peripheral blood of patients with non-small cell lung cancer (NSCLC); to examine the correlation of the mRNA levels between PD and BTLA in NSCLC.MethodsFlow cytometry was used to detect the expression of PD1 and BTLA on the surfaces of CD8+T cells and γδ+ T cells in the peripheral blood samples collected from 32 in-patients w...
Source: Chinese Medical Sciences Journal - Category: General Medicine Source Type: research
ins I Abstract Allogeneic cancer cell lines serve as universal source of tumor-associated antigens in cancer vaccines. Immunogenic high hydrostatic pressure-killed cancer cells derived from cell lines can be used for the generation of dendritic cell (DC)-based active cellular immunotherapy of non-small cell lung cancer (NSCLC). We investigated the expression of 12 known NSCLC tumor-associated antigens (TAA) (CEA, MAGE-A1, MAGE-A3, MAGE-A4, PRAME, hTERT, HER2, MUC1, Survivin, STEAP1, SOX2 and NY-ESO-1) in 6 NSCLC cell lines as candidates for the generation of DC-based lung cancer vaccine. We showed that the selecte...
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers [1], which are the leading cause of cancer-related morbidity and mortality worldwide [2]. With the use of Tyrosine kinase inhibitors (TKI) in NSCLC patients with epidermal growth factor receptor (EGFR) mutations, the survival of lung cancer patients with EGFR mutation has significantly improved [3]. However, 40% patients develop brain metastases (BM) during the disease and the risk of BM is higher in NSCLC patients with EGFR mutation than in those with wild-type tumors [4,5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 8 January 2020Source: Genes &DiseasesAuthor(s): Zhen Liu, Jiahao Liu, Yang Li, Hao Wang, Zixi Liang, Xiaojie Deng, Qiaofen Fu, Weiyi Fang, Ping XuAbstractThe presence of VPS33B in tumors has rarely been reported. Downregulated VPS33B protein expression is an unfavorable factor that promotes the pathogenesis of lung adenocarcinoma (LUAD). Overexpressed VPS33B was shown to reduce the migration, invasion, metastasis, and chemoresistance of LUAD cells to cisplatin (DDP) in vivo and in vitro. Mechanistic analyses have indicated that VPS33B first suppresses epidermal growth factor receptor ...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 8 January 2020Source: Journal of Bone OncologyAuthor(s): Guillaume Pontarollo, Cyrille B. Confavreux, Jean-Baptiste Pialat, Sylvie Isaac, Fabien Forest, Violaine Yvorel, Jean-Michel Maury, Nicolas Girard, Marie BrevetAbstractAs for molecular alterations of lung adenocarcinoma, it is critical that pathologists are able to give PD-L1 expression status before first-line of treatment. The present study compared PD-L1 expression (clone 22-C3) in decalcified using EDTA or formic acid and non-decalcified lung cancer metastases bone samples. Among the 84 bone samples analysed for PD-L1 expression...
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
Authors: Jin Y, Shen X, Pan Y, Zheng Q, Chen H, Hu H, Li Y Abstract Background: Programmed death ligand-1 (PD-L1) is a predictive marker of anti-programmed death protein 1 (PD-1)/PD-L1 therapies for non-small cell lung cancer (NSCLC). However, little is known between PD-L1 expression and the clinicopathological characteristics of NSCLC in the Chinese population in a real-world setting. Methods: We analyzed PD-L1 expression by immunohistochemistry (IHC) in NSCLC patients using the 22C3 clone on the Dako Autostainer Link 48 platform. We then examined the associations of PD-L1 expression with clinicopathological c...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Academia | Adenocarcinoma | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Databases & Libraries | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Radiation Therapy